Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 21,412 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase II Clear all

Conditions: Hormone-Resistant Prostate Cancer, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
Interventions: Docetaxel, Laboratory Biomarker Analysis, Prednisone, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine, Rilimogene Galvacirepvec; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 14
States / cities: Jacksonville, Florida • Chicago, Illinois • Highland Park, Illinois + 10 more

Conditions: Influenza
Interventions: VAX2012Q, Fluzone Quadrivalent; Biological
Lead sponsor: VaxInnate Corporation; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 6
States / cities: Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more

Conditions: Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: O6-benzylguanine, temozolomide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Cancer
Interventions: cisplatin, ixabepilone; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Unruptured Cerebral Aneurysm
Interventions: Standard Manual Aneroid Sphygmomanometer; Device
Lead sponsor: Sebastian Koch; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Ovarian Neoplasms
Interventions: SGN-15 (cBR96-Doxorubicin Immunoconjugate), Gemzar (Gemcitabine); Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 6
States / cities: Tucson, Arizona • San Diego, California • Torrance, California + 3 more

Conditions: Acute Myeloid Leukemia
Interventions: Phase I- Cytarabine & Eltrombopag, Phase II- Sequence A, Phase II- Sequence B; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more

Conditions: Lung Cancer
Interventions: gefitinib; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Transplantation, Homologous, Transplantation, Autologous, Multiple Myeloma, Blood and Marrow Transplant (BMT)
Interventions: Autologous peripheral blood stem cells (auto-PBSC) transplantation, Allogeneic peripheral blood stem cells (allo-PBSC) transplantation, Filgrastim, Cyclophosphamide, Melphalan, Cyclosporine, Total lymphoid irradiation, Rabbit anti-thymocyte globulin, Mycophenolate Mofetil 250mg, Solumedrol, Diphenhydramine, Acetaminophen, Hydrocortisone; Procedure · Drug · Radiation + 1 more
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Relapsed or Refractory Solid Tumors
Interventions: Lenvatinib; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 2 Years to 21 Years
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Aurora, Colorado • Cleveland, Ohio • Nashville, Tennessee + 1 more

Conditions: Hidradenitis Suppurativa, Acne Inversa
Interventions: INCB054707, Placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 25
States / cities: Hoover, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more

Conditions: Multiple Myeloma
Interventions: Trametinib; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Colorectal Cancer
Interventions: cyclosporine, CPT-11; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 10
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more

Conditions: Acute Lymphoblastic Leukemia (ALL)
Interventions: Moxetumomab Pasudotox; Biological
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 6 Months to 24 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 1 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: sargramostim, topotecan hydrochloride; Biological · Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2002
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Adenocarcinoma of Stomach, Adenocarcinoma of GE Junction, Adenocarcinoma of Esophagus
Interventions: Doxorubicin, Cisplatin, 5-fluorouracil; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Non-Alcoholic Steatohepatitis
Interventions: SHP626, Placebo; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 49
States / cities: Coronado, California • Fresno, California • Los Angeles, California + 42 more

Conditions: Diabetes Mellitus Type 2
Interventions: EGT0001442, Placebo capsules to match EGT0001442; Drug
Lead sponsor: Theracos; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Birmingham, Alabama • National City, California • Denver, Colorado + 4 more

Conditions: Infections, Gram-Positive Bacterial, Abscess, Burns, Cellulitis, Ulcer, Wound Infections
Interventions: Telavancin, Vancomycin or antistaphylococcal penicillin; Drug
Lead sponsor: Cumberland Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Esophageal Cancer
Interventions: gefitinib, oxaliplatin, conventional surgery, neoadjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Acute Pancreatitis
Interventions: CM4620; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 3
States / cities: Charlotte, North Carolina • Cincinnati, Ohio • Memphis, Tennessee

Conditions: Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: carboplatin, cisplatin, paclitaxel; Drug
Lead sponsor: Canadian Cancer Trials Group; Network
Eligibility: 18 Years and older · Female only
Enrollment: 275 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 6
States / cities: Springfield, Missouri • Oklahoma City, Oklahoma • Providence, Rhode Island + 2 more

Conditions: Autism Spectrum Disorder
Interventions: GWP42003-P, Placebo; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 12
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 9 more

Conditions: Neuroendocrine Tumors, Well-Differentiated Neuroendocrine Carcinoma, High Grade Neuroendocrine Carcinoma, Any Site
Interventions: Lenvatinib, Pembrolizumab, Hyperpolarized 13C-Pyruvate; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

BMS-247550 Plus Cisplatin in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Remote Ischemic PreConditioning (RIPC)

Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian Cancer

Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa

UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib

Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer

Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer

Doxorubicin, Cisplatin, 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus

Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)

Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

Phase 2 Trial of TD 6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer

Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase

Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer

Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors